/TLSI

TriSalus Life Sciences Inc

TLSI

$4.67USD↓-0.74%-0.04 today

MARKET CAP

287.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$2

$8

AI Summary

Stalk

StalkMedium

TLSI is in an early/fragile Stage 1 base after the mid-May flush; long-term downtrend remains intact but short-term EMAs have repaired and the Bullish Pivot Point signals structural repair. Price is oscillating in a tightening range above support but is extended above rising EMAs, so the medium-term bias is bullish while execution is best deferred. The strategy is to stalk pullbacks into the rising 9/21 EMA support zone in anticipation of a breakout.

↑Q1 2026 revenue $8.9M drives revised FY26 guidance of $54–$57M
↑52% YoY revenue growth underscores strong PEDD system adoption
↓FDA delays postpone Trinav Advance launch, reducing H2 revenue visibility

Full analysis →

Buying

3

institutions

Selling

2

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.66 M	12.10 M	+1.16 M	+101.7%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUYNEW	117.98 K	536.80 K	+117.98 K	+0.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	20.21 K	95.79 K	+8.81 K	+126.4%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	0.00	0.00	+-30.90 K	-100.0%	0.00%
MG Man Group Plc Q2 2026	SELL	0.00	0.00	+-23.36 K	-100.0%	0.00%